% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • trtlracer2013 trtlracer2013 Apr 19, 2014 1:22 PM Flag

    Barrons math......


    If the FDA signals a willingness to consider the drug for accelerated approval, based on the phase II data—which it was not willing to do in the fall—Sarepta shares could double from the current price of $24.20. The prevailing Street view is that the FDA will require a phase III trial before considering approval.

    Sarepta is valued at $922 million. Eteplirsen could initially produce $500 million of annual revenue if approved. The potential size of the DMD drug market is much larger, since eteplirsen addresses a genetic mutation affecting about 13% of DMD sufferers. Drug companies with lucrative drugs for orphan diseases, including Alexion Pharmaceuticals (ALXN), often are valued at more than 10 times revenue.

    Ok Barrons........10 x 500million = 1.85 biliion

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
60.98-1.26(-2.02%)Sep 29 4:00 PMEDT